Project Grant R43AR082785
Award Date
9/19/23
Completion Date
8/31/24
Dollars Obligated
$242K
Similar Awards
This $395,171 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports research to determine the in vivo chemical alteration processes of contemporary ultra-high molecular weight polyethylene (PE) tibial liners used in total knee arthroplasty (TKA) procedures. The research aims to understand how PE changes chemically in the body and the impact...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), aims to establish a new "microphysiological joint-on-chip" system for the study of arthritic diseases and rapid testing of treatment candidates. The $618,629 award, effective from August 15, 2024 to July 31, 2029, will fund the development of human-derived biomaterial inks and...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $299,996 to Flex Orthopaedics, Inc. to conduct late-stage pre-clinical studies on a novel compliant ankle endoprosthesis. The goal is to demonstrate the device's acute failure resistance under super-physiologic loads and its long-term durability to support human gait for decades, in...
This $312,871 Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), supports the development of a novel pro-angiogenic bone coating hydrogel (ABC hydrogel) to treat osteonecrosis (ON). The principal investigator, the University of Texas Southwestern Medical Center, will conduct research to determine the physical, chemical, and cytocompatibility properties...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), totaling $599,693, supports research focused on elucidating molecular pathways and mechanisms that regulate myeloid cell function and osteoclastogenesis under pathological inflammatory conditions, with the goal of developing new therapeutic approaches to suppress pathological bone...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $220,224 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to The Regents of the University of Colorado (CU) for the project "GRANULAR HYDROGELS FOR THE CONTROLLED DELIVERY OF IMMUNOMODULATORY AND ANGIOGENIC EXTRACELLULAR VESICLES TO ENHANCE BONE TISSUE REGENERATION". The grant, awarded on July 4, 2024, supports CU's research to develop novel...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is developing the X-Visual, a sensor to track fracture healing in cannulated screws used for hip fracture fixation. The $299,999 award to Aravis Biotech LLC will cover the design, computational modeling, and initial testing of this innovative device that can non-invasively measure screw bending...
This federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $526,174 to Duke University to engineer heterocellular human skeletal muscle tissues. The goal is to recreate and study the native stem cell niche function of healthy skeletal muscle, which is critical for its regenerative capacity. By incorporating capillary networks and functional...
This $644,887 federal Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) supports research to elucidate the role of the WNT16 signaling pathway in regulating chondrocyte (cartilage cell) biology and its potential to mitigate the development of hip osteoarthritis (OA). The research aims to determine the genetic and epigenetic mechanisms by which...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), provides $295,481 to support the development of MUSCLEINK, a multifunctional colloidal scaffold for the treatment of volumetric muscle loss (VML). VML refers to large-scale skeletal muscle deficits resulting from traumatic injury or tumor removal, which severely limits mobility and recovery in...